Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines.
OBJECTIVE
This study evaluated the cytotoxicity of five prostaglandin analog ophthalmic solutions on four ocular surface cell lines, ie, Chang (human conjunctiva), SIRC (rabbit cornea), RC-1 (rabbit cornea), and BCE C/D-1b (bovine cornea).


METHODS
Cell viability was measured by neutral red and MTT assays in cells treated for 10, 30, or 60 minutes with various doses of prostaglandins (undiluted, and 2- and 10-fold dilutions). The number of cell lines with viability >/=50% in the presence of selected dilution of the drug (CVS(50)) was used for comparison. In addition, 24 cell viability comparisons (four cell lines, two assays, and three exposure times) were made between latanoprost (Xalatan((R))) and each other solution at each dose. A comparison between the newly introduced tafluprost (Tapros((R))) with 0.01% benzalkonium chloride was also made.


RESULTS
The order of cell viability determined by CVS(50) was Travatan Z((R)) (travoprost with the SofZia system) > Tapros >/= Travatan((R)) (travoprost) = Xalatan > Rescula((R)) (unoproston). This was consistent with the results of direct comparisons between Xalatan and the other drugs. There was no clear difference in cell viability between Tapros and benzalkonium chloride.


CONCLUSIONS
Use of two assays, multiple cell lines, and various dilutions and exposure times provided a unique evaluation of cytotoxicity among ophthalmic solutions. CVS(50) was useful for comparison of the cell viability of the solutions.
Ayaki
Masahiko
M
Department of Ophthalmology, Saitama National Hospital, Wako City, Saitama, Japan. mayaki@olive.ocn.ne.jp
Iwasawa
Atsuo
A
J Ocul Pharmacol Ther. 2003 Feb;19(1):23-35
12648301
Ophthalmology. 1996 Jan;103(1):138-47
8628544
Clin Exp Ophthalmol. 2008 Aug;36(6):553-9
18954319
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619-30
10067965
Am J Ophthalmol. 2003 May;135(5):688-703
12719078
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4123-8
17724196
Exp Eye Res. 2000 Jan;70(1):113-20
10644427
Br J Ophthalmol. 2007 May;91(5):673-6
17124244
Lancet. 2004 May 22;363(9422):1711-20
15158634
Arch Ophthalmol. 2004 Feb;122(2):185-9
14769594
Br J Ophthalmol. 2008 Sep;92(9):1275-82
18723745
Exp Eye Res. 2000 May;70(5):563-9
10870514
J Ocul Pharmacol Ther. 2008 Oct;24(5):521-6
18808364
Curr Eye Res. 2008 Apr;33(4):303-12
18398704
Exp Eye Res. 1999 Oct;69(4):431-6
10504276
Ophthalmology. 2004 Mar;111(3):427-34
15019314
Invest Ophthalmol. 1976 Apr;15(4):246-59
1262158
Adv Ther. 2003 Jan-Feb;20(1):1-13
12772813
Am J Ophthalmol. 2003 Mar;135(3):314-20
12614748
Invest Ophthalmol Vis Sci. 2004 May;45(5):1360-8
15111589
Cornea. 2008 Apr;27(3):339-43
18362664
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4594-9
16303954
Clin Ophthalmol. 2010 Sep 20;4:1019-24
20922036
Surv Ophthalmol. 1997 Feb;41 Suppl 2:S129-38
9154289